Targeting Components of Distress Tolerance
NCT06570603
Recruiting
The goal of this clinical trial is to learn which aspects of distress intolerance (i.e., difficulties withstanding upsetting emotional states) are the most important for improving effective emotion regulation and associated mental health symptoms. The main questions it aims to answer are: How are willingness to feel upset and self-efficacy for withstanding distress associated with different emotion regulation strategies used in daily life? Does targeting willingness to feel upset and/or self-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of Arkansas - Fayetteville, Fayetteville, Arkansas
Conditions: Distress, Emotional
Register for Updates
Pragmatic Clinic-Based Trial of a Mindfulness Based Intervention for Mood Concerns in Youth With Type 1 Diabetes
NCT06618027
Recruiting
Type 1 diabetes (T1D) is a common chronic illness among children requiring a high degree of self-management for good glycemic control. Adolescents are at risk for poor disease management and health outcomes due to a number of factors, including high rates of depression, anxiety, and stress. Accessing support for these challenges can be a barrier to care, so the current study, BRinging Empowerment and Attention to Teen HEalth-T1D, evaluates the efficacy of a virtual, group-based mindfulness based... Read More
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
07/07/2025
Locations: Barbara Davis Center, Aurora, Colorado +1 locations
Conditions: Type 1 Diabetes (T1D)
Register for Updates
Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
NCT06646627
Recruiting
This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Stanford University, Palo Alto, California
Conditions: Ovarian Cancer
Register for Updates
JIT: Effect of Pain on DT in TMD
NCT06659991
Recruiting
Individuals with chronic temporomandibular disorder (TMD) pain are at increased risk for alcohol-related consequences compared to those without pain, and growing evidence suggests pain is a potent motivator for alcohol use in many individuals. However, few systematic examinations of modifiable and non-modifiable risk factors, including orofacial pain status, have been conducted. This project addresses this gap in knowledge by determining the effect of pain on drinking topography in heavy drinker... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/07/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Temporomandibular Disorder (TMD)
Register for Updates
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
NCT06662188
Recruiting
This is a Phase 1/2, first in human, open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of JAG201 administered via intracerebroventricular (ICV) injection in pediatric and adult participants with SHANK3 haploinsufficiency resulting from SHANK3 loss of function mutations and chromosomal deletions encompassing the SHANK3 gene. Clinical data will be evaluated for safety, tolerability, and preliminary clinical activity of JAG201 in pediatri... Read More
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
07/07/2025
Locations: Rush University, Chicago, Illinois +2 locations
Conditions: SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
Register for Updates
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
NCT06662994
Recruiting
Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues. Patients may have improved DME with anti-VEGF therapy and ranibizumab has been found to reduce central macular thickness (CMT) with anti-VEGF therapy following vitrectomy. Those patients still require intravitreal injections but the pharmacokinetics of a vitrectomized eye are different than those eyes that have not undergone vitrectomy. The clearance of protein... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/07/2025
Locations: Retina Consultants of Orange County, Fullerton, California
Conditions: Diabetic Macular Edema (DME)
Register for Updates
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132
Recruiting
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of California - Los Angeles - 300208353, Santa Monica, California +30 locations
Conditions: Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Register for Updates
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
NCT06710288
Recruiting
This is phase 2 single arm study evaluating the safety and preliminary efficacy of M-CENK adoptive cell therapy and fixed dose of N-803 in combination with gemcitabine in participants with platinum-resistant high-grade ovarian cancer (HGOC).Up to 20 participants will receive M-CENK (IV) and N-803 (SC) in combination with gemcitabine (IV). Participants will undergo an apheresis procedure for the collection of mononuclear cells (MNCs) at least 1 day prior to Cycle 1 for manufacturing of M-CENK. S... Read More
Gender:
FEMALE
Ages:
Between 18 years and 85 years
Trial Updated:
07/07/2025
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California +1 locations
Conditions: Platinum-resistant Ovarian Cancer
Register for Updates
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
NCT06719362
Recruiting
Phase 1 first-in-human, open-label, dose-escalation (3 + 3), dose-expansion clinical trial to evaluate the safety, tolerability and preliminary clinical efficacy of M3T01 (fully human IgG4/kappa monoclonal antibody targeting FasL) in subjects with metastatic or unresectable solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon
Conditions: Advanced Solid Tumors
Register for Updates
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
NCT06731894
Recruiting
This phase II trials evaluates how well different types of phytocannabinoids (cannabidiol \[CBD\] versus tetrahydrocannabinol \[THC\] and CBD formulation \[THC:CBD\]) work to reduce chronic chemotherapy-induced peripheral neuropathy among breast and colon cancer survivors. Chemotherapy induced peripheral neuropathy is a set of symptoms that includes pain, tingling, numbness and motor weakness caused by certain types of chemotherapy treatment. Phytocannabinoids are compounds made by the cannabis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: City of Hope Medical Center, Duarte, California +1 locations
Conditions: Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
Register for Updates
A Pivotal Study to Evaluate the Effectiveness of Isometric Handgrip Therapy in Elevated Blood Pressure and Hypertensive Subjects
NCT06843577
Recruiting
The study will be a multi-center, randomized clinical trial to evaluate the safety and efficacy of using the Zona Plus handgrip therapy device compared to the use of an auditory relaxation therapy for treatment of high blood pressure and hypertension in subjects who are not currently taking antihypertensive medications. Half of the study subjects will also be randomized to record blood pressure at home throughout the study.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
07/07/2025
Locations: Bayview Research Group, Valley Village, California +4 locations
Conditions: Elevated Blood Pressure, Hypertension
Register for Updates
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion
NCT06855771
Recruiting
The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Alaska Oncology and Hematology, Anchorage, Alaska +70 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates